Regeneron Pharmaceuticals (NASDAQ:REGN) said Monday that partner Hansoh Pharmaceutical Group Company Limited reported ...

Hansoh’s olatorepatide achieved 19% weight loss at 48 weeks in a Phase 3 trial in China, handing partner Regeneron a glimmer ...

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.

China approves Pfizer’s GLP-1 weight-loss drug, expanding competition in the booming obesity treatment market and highlighting rising metabolic health concerns.

Eli Lilly (LLY) files a China marketing application for the oral GLP-1 weight loss drug orforglipron and pledges a $3B ...

Ecnoglutide is distinguished by its selective activation of the cAMP signalling pathway, reducing β-arrestin recruitment.

Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the country’s National Medical Products Administration (NMPA) has ...

A new, strange phenomenon called the “plastic eating” trend for weight loss is gaining momentum in China on TikTok. According to clips doing the rounds on the internet, people, especially youngsters, ...

Eli Lilly said the US drugmaker plans to invest USD3 billion in China over the coming decade to expand supply-chain ...

Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks ...

Eli Lilly plans to invest $3 billion in China over the next decade, which ​will help build production capacity for its experimental ‌type-2 diabetes and obesity treatment orforglipron, the U.S.